Freestone Grove Partners LP Takes $14.72 Million Position in Supernus Pharmaceuticals, Inc. $SUPN

Freestone Grove Partners LP purchased a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 316,398 shares of the specialty pharmaceutical company’s stock, valued at approximately $14,716,000.

Several other hedge funds have also recently made changes to their positions in the stock. BlackRock Inc. bought a new position in Supernus Pharmaceuticals during the second quarter valued at approximately $434,871,000. State Street Corp grew its position in Supernus Pharmaceuticals by 1.4% in the 4th quarter. State Street Corp now owns 2,219,228 shares of the specialty pharmaceutical company’s stock worth $110,296,000 after purchasing an additional 31,668 shares during the period. Geode Capital Management LLC raised its stake in Supernus Pharmaceuticals by 4.5% during the 4th quarter. Geode Capital Management LLC now owns 1,472,899 shares of the specialty pharmaceutical company’s stock valued at $73,215,000 after buying an additional 62,875 shares during the last quarter. Loomis Sayles & Co. L P raised its stake in Supernus Pharmaceuticals by 12.7% during the 4th quarter. Loomis Sayles & Co. L P now owns 1,448,842 shares of the specialty pharmaceutical company’s stock valued at $72,007,000 after buying an additional 162,905 shares during the last quarter. Finally, Stephens Investment Management Group LLC lifted its holdings in shares of Supernus Pharmaceuticals by 4.5% during the 4th quarter. Stephens Investment Management Group LLC now owns 1,406,522 shares of the specialty pharmaceutical company’s stock valued at $69,904,000 after buying an additional 61,120 shares during the period.

Analyst Ratings Changes

Several brokerages have issued reports on SUPN. Weiss Ratings reissued a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Wednesday, June 24th. Wall Street Zen cut shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Zacks Research raised shares of Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 6th. Finally, Cantor Fitzgerald increased their price target on shares of Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an “overweight” rating in a research report on Thursday, July 9th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Supernus Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $62.83.

Supernus Pharmaceuticals Stock Down 1.5%

NASDAQ SUPN opened at $44.19 on Friday. Supernus Pharmaceuticals, Inc. has a 52 week low of $42.45 and a 52 week high of $59.68. The company has a market capitalization of $2.57 billion, a P/E ratio of -23.02, a price-to-earnings-growth ratio of 0.83 and a beta of 0.56. The stock’s 50-day moving average price is $46.83 and its 200-day moving average price is $48.69.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings data on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.42 by ($1.43). The company had revenue of $219.06 million for the quarter, compared to the consensus estimate of $205.31 million. Supernus Pharmaceuticals had a negative net margin of 13.23% and a positive return on equity of 11.13%. The company’s revenue was up 32.4% compared to the same quarter last year. During the same quarter last year, the firm posted $0.40 earnings per share. Research analysts anticipate that Supernus Pharmaceuticals, Inc. will post 1.97 EPS for the current year.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.